#1CYTEK TRANSCEND THE CONVENTIONAL Corporate Presentation November 2023 Dr. Wenbin Jiang, CEO Patrik Jeanmonod, CFO Paul Goodson, Investor Relations#2Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's business and operational goals and strategies; Cytek's business development plans; Cytek's estimated market size and opportunities; Cytek's prospective products; objectives of management for future operations; and the expected key strategic benefits from the flow cytometry and imaging business acquired from Luminex. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentation, including, without limitation, statements The words "may," "will," "expect," "anticipate," "aim," "estimate,” “intend,” "plan," "believe," "is/are likely to," "potential," "continue" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks relating to global economic and market conditions; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to successfully integrate the acquired Luminex business and recognize the anticipated benefits of the transaction; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and retain key employees; Cytek's ability to maintain, protect and enhance its intellectual property; and Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. Information on these and additional risks and uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Certain information contained in this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cytek's internal estimates and research. While Cytek believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Cytek believes its internal research is reliable, such research has not been verified by any independent source. Cytek's estimates are derived from publicly available information, management's knowledge of the Cytek's industry and management's assumptions based on such information and knowledge, which they believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. This presentation includes certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the twelve months ended September 30, 2023. Management believes that non-GAAP financial measures, including "Adjusted EBITDA", taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company's core operating results. Management uses non-GAAP measures to compare the company's performance relative to forecasts and strategic plans and to benchmark the company's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the tables accompanying this presentation. Cytek, Full Spectrum Profiling, FSP, Northern Lights, Cytek Aurora, cFluor, Tonbo, Amnis, Guava, Muse, ImageStream, FlowSight, CellStream and easyCyte are trademarks of Cytek Biosciences, Inc. Other trademarks appearing in this presentation are the property of their respective holders. CYTEK TRANSCEND THE CONVENTIONAL 2#3Cytek's Leadership Team Wenbin Jiang, Ph.D. Chief Executive Officer Cosemi LUMENTUM Valerie Barnett General Counsel Dermira FLUIDIGM WILSON SONSINI Ming Yan, Ph.D. Chief Technology Officer BD NeoPhotonics Philippe Busque SVP, Global Sales and Services SONY BIOTECHNOLOGY BD Abbott Patrik Jeanmonod Chief Financial Officer COVANCE CORE BRANDS Allen Poirson, Ph.D. SVP, Corporate and Business Development Acculmage two AR SONY BIOTECHNOLOGY Chris Williams Chief Operating Officer Thermo Fisher SCIENTIFIC Paul Goodson Head of Investor Relations Invitrogen seauenom.XOMA living science CYTEK TRANSCEND THE CONVENTIONAL 32#4Investing to Capture the Cell Analysis Opportunity¹ Broad Customer Base and Global Presence Strong Financial Profile Validated Technology Platform 1. 1,997 Cytek Units Placed 1,450+ Cytek Peer-Reviewed Publications Nine months ended September 30, 2023 except as otherwise noted. 1,500+ Customers 70+ Countries $183.1M $9.3M TTM Revenue/ A-EBITDA $288M 9/30/23 Cash and Equivalents Luminex CE-IVDD Tonbo™ Cell Sorter Reagents Northern TM Lights ™M Cytek Aurora ™M 288 CYTEK TRANSCEND THE CONVENTIONAL 0 2023 2022 2021 2021 2020 2018 2017 4#5Global Scale and Reach with Diversified Revenue Mix Since launch of Aurora Series in 2017¹... 1,500+ Customers 150+ Biopharma Companies 70+ Countries -700 Employees WW Applications, Service & Sales % Revenue by Industry 1. 59% 41% Seattle Nine months ended September 30, 2023 Fremont (Headquarters) Academic and Government-Owned Institutions ■ Pharmaceutical and Biotechnology Companies, Distributors and CROS San Diego Bethesda Amsterdam % Revenue by Region USA 56% EMEA 25% Wuxi Shanghai Tokyo APAC & ROW 19% CYTEK TRANSCEND THE CONVENTIONAL 5#6Acquisition of Luminex's Flow Cytometry and Imaging Business¹ provides key strategic benefits 1 Enhances technical capabilities Enhanced Al-driven analytical performance from high- resolution cell imagery CYTEK TRANSCEND THE CONVENTIONAL Capillary micro fluidics allows for reduced cost of goods, higher gross margins and improved ease of use (1) Acquisition closed February 28, 2023 2 Expands customer base and commercial reach 7,000+ Units Placed 70+ Countries 1,500+ Customers Expect replacement upgrades to Northern Lights and Aurora platforms 3 Significant operational synergies across service Quicker access by field personnel More effective and efficient Service / Support Enables future expansion of service gross margins Positions Cytek for future clinical expansion 6#7CYTEK AURORA Broad product portfolio to capture the cell analysis opportunity Aurora 2017 CYTEK TRANSCEND THE CONVENTIONAL ImageStream Mk CYTEK™ Northern Lights 2018 amnis Luminex Amnis ImageStreamⓇ Amnis® & GuavaⓇ 2023 Flow Sight Reagents 2020 amnis Luminex Amnis FlowSightⓇ 44048 Cell Sorter 2021 amnis Luminex Amnis CellStreamⓇ Luminex Cerin Tonbo 2021 Guarva easyCyte EXTER Guava easyCyteⓇ 117. MORB D Cuminer Qara CITIES Com CE-IVDD 2022 Guava® MuseⓇ 7#8Cytek Technology Enables Applications Total Peer Reviewed Scientific Publication by Application 20.40% 13.30% 17.20% 23.30% 25.80% ■ Oncology ■ Vaccines/Viral infection ■ Immunology/Therapies Inflammation/Autoimmunity Drug Development/other Cell Cancer Research AAGR JCI INSIGHT Tumor-specific Mex agar patters of resistance to immanetes A The Journal of Immunology nature Advances INSIDE GREEN FLUORESCENT PROTEIN Then that pow in the whit and the 1,450+ Cytek Peer-Reviewed Publications NAMAS 8#9Why Customers Choose Cytek . $ (8 Deeper assessment of patient immune status -- before and after treatment -- for many applications including cancer, COVID, inflammation, drug discovery Fully Standardized across experiments and laboratory sites More powerful system at a lower cost with minimal learning curve Isolate rare cells that cannot be seen on other systems for deeper insights Maximize the value of a lab sample with more information in less time with fewer errors Over 1,450+ scientific peer-reviewed publications in less than 5 years CYTEK TRANSCEND THE CONVENTIONAL 9#10We Provide an End-to-End Platform of FSP Solutions Aurora Cell Sorter Specificity CD3 CD14 CD45 Violet Instruments Fluorochrome cFluor V420 cFluor V450 cFluor V547 CYTEK TRANSCEND THE CONVENTIONAL Specificity CD8 CCR7 IqD CD45RA CD19 CD25 Blue Northern Lights Fluorochrome cFluor B515 cFluor BYG575 cFluor BYG667 cFluor 8690 cFluor BYG710 cFluor BYG781 Automatic sample loader FOOTER Specificity CD127 CD16 CD56 CD4 Viability CD27 Red Fluorochrome cFluor R659 cFluor R668 cFluor R720 Services & Application support cFluor R780 ViaDye Red cFluor R840 Reagents and Kits 0000 CYTEK FULL SPECTRUM S-LASER CYTOMETRY AT A GLANCE EXTER CYTEK SURAS Dimensionality Reduction CYTEK Data Acquisition and Analysis Software 10#11More markers per tube, makes tests more powerful and cost-effective Conventional Flow Cytometry Clinical Labs 12 Markers per tube CYTEK TRANSCEND THE CONVENTIONAL Research Labs 30-40 Markers per tube Cytek Flow Cytometry Full Spectrum Profiling TM Technology Clinical & Research Labs 40 Markers per tube Blue Channels Ignored V/G Channels "Dirty" Data Red Channels Compensated "Clean" Data 700 High sensitivity and high throughput without compromising data quality Allows use of many dyes simultaneously with optimal resolution Able to extract autofluorescence to enhance resolution 11#12Cytek's Four Business Pillars Instruments Performance ● ● Intelligence Ease of use Compact Lowest cost CYTEK TRANSCEND THE CONVENTIONAL UNNA FOOTNOTE Applications Enabler Panels/kits Flexibility Functionality/Purposes Volume/repeating UNNA Bioinformatics Storage Analysis ● ● Optimization Management Exchanges UNNA Clinical ● ● ● ● ● Regulatory LDT Menu AI Standardization UNNA 12#13Cytek's Operational and Shareholder Goals Capital Efficiency Operation Excellence CYTEK TRANSCEND THE CONVENTIONAL Maximize Free Cash Flow FOOTNOTE Commitment to Shareholder Value Creation Maintain Positive A-EBITDA on annual basis Execution Speed Smart Acquisitions, Licenses and Joint Ventures 13#14CYTEK TRANSCEND THE CONVENTIONAL (R) Thank You#15CYTEK TRANSCEND THE CONVENTIONAL Appendix (R)#16C Our FSP Technology is Powered by Patented Innovative Designs 4 LT DEPRE APD DETECTOR MODULE DETAL CE EXTR TI FE EICKJ DE EXTRA CYTEK AUKORA CYTEK TRANSCEND THE CONVENTIONAL Maximize Resolution & Accuracy JETEC URN VIRDCAS LASERS A WAPD DETECTOR MODULE FOOTNOTE VIOLET APD DETECTOR MODULE FLOW CELL SAPO DETECTOR MODULE SAMPLE FIBER OPTICS RED AND DETECTOR MODULE YİGRIN APA DEYSICIOR MODULE Optimized Signal-to-Noise Ratio B LTRAVIOLET 12 CHANNELS VIOLET CHANNELS GLUC C4 CHANNELS) SPECTROFLO DISPLAY RED YELLOW-GREEN CHANNELS IN CHANNELS High Resolution NRCOME PRIMER D 100 quantum efficiency (%) 10 0.1 200 PMT APD photodiode 400 800 600 wavelength (nm) Valuable Insights 1000 1200 A The fluorescence spectrum from each laser source is collected from multiple laser excitation B The fluorescence from each laser source is collected by each corresponding detector array module C Use of APD detectors maximizes sensitivity and enables broad wavelength responses D The combination of our patented optical design with APD detectors yields high- resolution data at an optimized signal-to-noise ratio 16#17Advancing Cell Analysis with Our Unique FSP Technology Cytek's FSP™M Technology Conventional 80 80 70 80 50 20 10 ^ 300 Ignored PE Channel Compensated CYTEK TRANSCEND THE CONVENTIONAL 750 FITC = Green!... or emission from 515-545 (530/30 BP) PE cFluor YG584 FOOTNOTE UV Channels Violet Channels Blue Channels Y/G Channels Unmixing algorithm ENTIRE emission spectrum is captured across the different module & stitched together to create a spectral signature that combines emission information of fluorochrome excited by all onboard lasers Red Channels CD8 APC 13 APC Alexa Fluor 647 0 4.0M- 3.0M- 2.OM- 1.0M- NK cells NK cells Aurora Full Spectrum 10¹ 10² CD56 Alexa 647 Non T cells 010 APC 10¹ Unmixing T cells 104 CD3 FITC CD8 APC 10. 10³- -10- Alexa Fluor 647 -10* 10⁰ NK T cells NK T cells 0 10¹ 10² CD56 Alexa 647 Our FSP platform was purpose- built to advance the next generation of cell analysis by delivering deep insights, high throughputs and ease of use FSP technology enables high sensitivity and high throughput without compromising data quality Allows use of many dyes simultaneously with optimal resolution, which is not possible with conventional cytometers FSP is able to extract autofluorescence to enhance resolution 17#18GAAP to Non-GAAP (GP and EBITDA) September 30, 2023 (In thousands) GAAP gross profit Stock Based Compensation Amortization of acquisition-related Intangib Non-GAAP Gross Profit GAAP gross profit % Non-GAAP gross profit % GAAP Net (loss) income Depreciation and Amortization Provision (Benefit) for Tax Interest Income Interest Expense Foreign Currency exchange loss Loss on lease exit cost Stock Based Compensation Acquisition related expenses Adjusted EBITDA CYTEK TRANSCEND THE CONVENTIONAL $ $ $ $ 27,178 $ 829 458 28,465 $ 57% 59% (6,456) $ 2,561 2,271 (1,622) 595 613 5,758 3,720 $ June 30, 2023 28,162 $ 868 539 29,569 $ 57% 60% (4,388) $ 2,445 (2,207) (1,201) 409 535 5,922 27 1,542 $ March 31, 2023 December 31, 21,038 $ 692 223 21,953 $ 57% 59% (6,807) $ 1,801 (2,233) (2,143) 673 (1) 4,699 1,485 (2,526) $ 2022 September 30, 2022 29,374 $ 640 65 30,079 $ 61% 62% 3,718 $ 1,465 396 (2,626) 687 (1,748) 4,465 218 6,575 $ 26,862 $ 759 64 27,685 $ 66% 68% 1,626 $ 1,452 224 (1,584) 649 570 4,359 7,296 $ June 30, 2022 24,561 $ 749 64 25,374 $ 61% 63% (702) $ 1,356 (699) (391) 647 331 3,934 4,476 $ March 31, 2022 December 31, 20,177 $ 707 57 20,941 $ 58% 60% (2,158) $ 1,294 (1,145) (18) 590 422 3,837 2,822 $ 2021 September 30, 2021 23,636 $ 717 50 24,403 $ 61% 63% (1,165) $ 685 1,609 (18) 492 295 347 3,008 230 5,483 $ 21,277 $ 559 21,836 $ 62% 64% 1,420 $ 189 655 (12) 441 388 2,455 5,536 $ June 30, 2021 19,745 $ 120 19,865 $ 65% 65% 2,670 $ 201 597 433 135 667 4,694 $ March 31, 2021 14,486 112 14,598 60% 60% 102 167 50 (10) 375 663 456 1,803 18